Hydroxy cycloalkyl fused pyridone carboxylic acid M(1) positive allosteric modulators.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2010-04-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2010.02.095PMID 20346667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• N-heterocyclic derived M1 positive allosteric modulators.

  2010cited by this paper
• Heterocyclic fused pyridone carboxylic acid M(1) positive allosteric modulators.

  2010cited by this paper
• Pyridine containing M(1) positive allosteric modulators with reduced plasma protein binding.

  2010cited by this paper
• Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

  2009cited by this paper
• A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning

  2009cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation

  2009cited by this paper
• Muscarinic acetylcholine receptors as CNS drug targets.

  2008cited by this paper
• Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats

  2008cited by this paper
• Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.

  2001cited by this paper
• Abnormalities of neural circuitry in Alzheimer's disease

  1998cited by this paper
• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.

  1996cited by this paper
• The molecular basis of muscarinic receptor diversity.

  1989cited by this paper
• New subtypes of muscarinic acetylcholine receptors.

  1989cited by this paper
• Studies on quinoline derivatives and related compounds. III. A novel pyridine synthesis to give substituted 1,4-dihydro-4-oxonicotinic acids†

  1975cited by this paper
• The Synthesis of Certain Substituted Quinolines and 5,6-Benzoquinolines

  1939cited by this paper

• Synthesis of α-enaminones from cyclic ketones and anilines using oxoammonium salt as an oxygen transfer reagent

  2020cites this paper
• N-alkyl 2-pyridone versus O-alkyl 2-pyridol: Ultrasonic synthesis, DFT, docking studies and their antimicrobial evaluation

  2020cites this paper
• Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.

  2015cites this paper
• Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M ₁ muscarinic acetylcholine receptor.

  2014cites this paper
• SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs).

  2014cites this paper
• Development of a photoactivatable allosteric ligand for the m1 muscarinic acetylcholine receptor.

  2014cites this paper
• Discovery of naphthyl-fused 5-membered lactams as a new class of m1 positive allosteric modulators.

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs interacting with Receptors. Update 2014

  2014cites this paper
• Catalytic intermolecular β-C-H alkenylation of α-enamino-ketones with simple alkynes.

  2014cites this paper
• Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor.

  2013cites this paper
• Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors

  2012cites this paper
• Novel M1 allosteric ligands: a patent review

  2012cites this paper
• Identification of amides as carboxylic Acid surrogates for quinolizidinone-based m1 positive allosteric modulators.

  2012cites this paper
• M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease

  2012cites this paper
• Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold.

  2011cites this paper
• Quinolizidinone carboxylic acids as CNS penetrant, selective m1 allosteric muscarinic receptor modulators.

  2010cites this paper